Antibody Drug Conjugate - Market Insights, Competitive Landscape, and Market Forecast - 2030

Antibody Drug Conjugate - Market Insights, Competitive Landscape, and Market Forecast - 2030

Antibody Drug Conjugate Market By Cancer Type (Breast Cancer, Lung Cancer, Bladder Cancer, Brain Tumor, And Others), Target Type (CD19, HER2, CD22, And Others), End-User (Hospitals And Specialty Cancer Centers, Biotechnology And Pharmaceutical Companies, And Others), And Geography (North America, Europe, Asia-Pacific, And Rest Of The World) is expected to grow at a steady CAGR forecast till 2030 owing to the growing prevalence of cancer and increasing R&D activities and clinical trials for development of antibody drug conjugate

The global antibody drug conjugate market was valued at USD 10.13 billion in 2023, growing at a CAGR of 14.37% during the forecast period from 2024 to 2030 to reach USD 25.79 billion by 2030. The demand for antibody-drug conjugates is primarily being boosted by the growing prevalence of cancer globally, increasing research & development activities, and clinical trials for the development of antibody-drug conjugates, during the forecast period from 2024-2030.

Antibody Drug Conjugate Market Dynamics:

According to the International Agency for Research on Cancer (IARC) report 2022, there were almost 20 million new cases of cancer and close to 10 million deaths from cancer in 2022. Demographics-based predictions indicated that the annual number of new cases of cancer will reach 35 million by 2050, that is, a 77% increase from the number in 2022. The increasing number of people affected with cancer is expected to drive the demand for antibody-drug conjugates in the forecasted period, thus resulting in the positive growth of the antibody-drug conjugate market.

Further, the growing research & development activities and clinical trials will create a significant opportunity to drive the market for antibody-drug conjugates. For instance, in March 2023, Ambrx Biopharma Inc. announced that it had been informed by its partner, NovoCodex Biopharmaceuticals, Inc., that an interim analysis for ACE-Breast-02, a randomized Phase 3 breast cancer clinical trial investigating Ambrx’s ARX788, an anti-HER2 antibody-drug conjugate, has met its pre-specified interim primary efficacy endpoint with statistical significance, demonstrating a greater progression-free survival (PFS) benefit compared to the active control.

On the other hand, in February 2022, Piramal Pharma, an Indian CDMO, invested 55 million pounds sterling ($74.4 million) to expand its antibody-drug conjugate and active pharmaceutical ingredient (API) manufacturing facilities in the U.K. This investment will boost the R&D of novel ADC drug capabilities in the UK.

Thus, due to the interplay of all the above-mentioned factors, the demand for Antibody Drug Conjugates will increase, thus resulting in the overall growth of the Antibody Drug Conjugates market.

However, the various side effects associated with antibody-drug conjugates, and the high manufacturing cost of antibody-drug conjugates, may act as factors that are expected to limit the growth of the antibody drug conjugates market.

Antibody Drug Conjugate Market Segment Analysis:

Antibody Drug Conjugate Market by Cancer Type (Breast Cancer, Lung Cancer, Bladder Cancer, Brain Tumor, and Others), Target Type (CD19, HER2, CD22, and Others), End-User (Hospitals and Specialty Cancer Centers, Biotechnology and Pharmaceutical Companies, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the cancer type segment of the antibody drug conjugate market, the breast cancer category is estimated to amass a significant revenue share in the antibody drug conjugate market in 2023. This can be attributed to the large patient population associated with breast cancer and the rising product development activities and availability of drugs related to breast cancer.

As per the 2024 report by the World Health Organization (WHO), breast cancer emerged as the most prevalent cancer among women in 157 out of 185 countries in 2022. During the same period, there were 2.3 million reported cases of breast cancer globally, resulting in 670,000 deaths. Breast cancer can affect women worldwide following puberty, with rates escalating in later stages of life. This widespread incidence of cancer fuels the demand for antibody-drug conjugates.

Moreover, recent approvals for breast cancer treatments are anticipated to spur growth in this segment. For instance, in August 2022, the FDA greenlit fam-trastuzumab deruxtecan-nxki (marketed as Enhertu) for adult patients with unresectable or metastatic HER2-low breast cancer, particularly those who have undergone prior chemotherapy or experienced disease recurrence within six months of completing adjuvant chemotherapy.

Thus, given the ongoing product launches and the escalating cases of breast cancer, this category is poised to propel the overall growth of the antibody-drug conjugate market during the forecast period.

North America Is Expected To Dominate The Overall Antibody Drug Conjugate Market:

North America is expected to account for the highest proportion of the antibody drug conjugate market in 2023, out of all regions. This is due to the significant burden of cancer, with a high incidence rate across various types of malignancies in the region. Additionally, North America is home to a robust biopharmaceutical industry comprising numerous companies engaged in the research, development, and commercialization of antibody-drug conjugate therapies. These companies benefit from access to advanced infrastructure, research funding, and a skilled workforce. These are some of the key factors driving the growth of the Antibody Drug Conjugate market in North America.

According to the American Cancer Society's Cancer Facts and Figures 2024 report, approximately 2 million new cancer cases are expected to be diagnosed in 2024 in the United States alone. Among these, prostate cancer is estimated at 299,010 cases, followed by lung cancer at 234,580 cases, and female breast cancer at 310,720 cases, demonstrating a rapid increase in the incidence of cancer cases in the country.

In addition, the various regulatory approvals for antibody-drug conjugate by the FDA are also expected to propel the market demand for antibody-drug conjugate. For example, in April 2024, AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) was approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DoR). Thus, the rising incidence of cancer in North America along with the various product launch activities taking place will eventually drive the overall market for antibody drug conjugate in North America during the forecast period.

Antibody Drug Conjugate Market Key Players:

Some of the key market players operating in the Antibody Drug Conjugate market include F. Hoffmann-La Roche Ltd, DAIICHI SANKYO COMPANY, LIMITED, Pfizer Inc., Gilead Sciences, Inc., ADC Therapeutics SA., GSK plc, Mersana Therapeutics., Astellas Pharma Inc., AstraZeneca, ImmunoGen Inc.

Recent Developmental Activities In The Antibody Drug Conjugate Market:

In July 2023, ImmunoGen, Inc., entered into a multi-target license and option agreement with ImmunoBiochem to develop next-generation antibody-drug conjugates.

In July 2023, BeiGene and DualityBio entered into a partnership to advance differentiated antibody-drug conjugate (ADC) therapy for solid tumors.

In June 2023, Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering. The acquisition comprises an initial financial consideration of €100 million in cash and up to €60 million in additional performance-based consideration.

Key Takeaways From The Antibody Drug Conjugate Market Report Study

Market size analysis for current Antibody Drug Conjugate Market size (2023), and market forecast for 6 years (2024-2030)

Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years

Key companies dominating the global Antibody Drug Conjugate market.

Various opportunities are available for the other competitors in the Antibody Drug Conjugate Market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current Antibody Drug Conjugate market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for Antibody Drug Conjugate market growth in the coming future?

Target Audience Who Can Be Benefited From This Antibody Drug Conjugate Market Report Study

Antibody Drug Conjugate product providers

Research organizations and consulting companies

Antibody Drug Conjugate-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in Antibody Drug Conjugate

Various end-users who want to know more about the Antibody Drug Conjugate Market and the latest technological developments in the Antibody Drug Conjugate Market.

Frequently Asked Questions For The Antibody Drug Conjugate Market:

1. What are Antibody Drug Conjugate?

Antibody-drug conjugates are a class of targeted cancer therapies designed to deliver cytotoxic (cell-killing) drugs specifically to cancer cells while sparing healthy tissues.

2. What is the market for Antibody Drug Conjugate?

The global antibody drug conjugate market was valued at USD 10.13 billion in 2023, growing at a CAGR of 14.37% during the forecast period from 2024 to 2030 to reach USD 25.79 billion by 2030.

3. What are the drivers for the global Antibody Drug Conjugate market?

The Antibody Drug Conjugate Market is slated to witness prosperity owing to the growing prevalence of cancer globally, increasing research & development activities, and clinical trials for the development of antibody-drug conjugates, during the forecast period from 2024-2030.

4. Who are the key players operating in the global Antibody Drug Conjugate market?

Some of the key market players operating in the Antibody Drug Conjugate include F. Hoffmann-La Roche Ltd, DAIICHI SANKYO COMPANY, LIMITED, Pfizer Inc., Gilead Sciences, Inc., ADC Therapeutics SA., GSK plc, Mersana Therapeutics., Astellas Pharma Inc., AstraZeneca, ImmunoGen Inc.

5. Which region has the highest share in the global Antibody Drug Conjugate market?

North America is expected to dominate the overall Antibody Drug Conjugate market during the forecast period from 2024 to 2030. This is due to the significant burden of cancer, with a high incidence rate across various types of malignancies in the region. Additionally, North America is home to a robust biopharmaceutical industry comprising numerous companies engaged in research and development are some of the key factors driving the growth of the Antibody Drug Conjugate market in North America.